FDA Approval of 18 F-Flurpiridaz for PET: Stepping into a New Era of Myocardial Perfusion Imaging?

作者：Thomas H. Schindler, Timothy M. Bateman, Daniel S. Berman, Panithaya Chareonthaitawee, Lorraine E. De Blanche, Vasken Dilsizian, Sharmila Dorbala, Robert J. Gropler, Leslee L. Shaw, Prem Soman, David E. Winchester, Hein J. Verberne, Sukhjeet Ahuja, Rob Beanlands, Marcelo F. Di Carli, Venkatesh L. Murthy, Terrence D. Ruddy, Ronald G. Schwartz · 发表于：Journal of Nuclear Medicine · 年份：2025 · DOI：10.2967/jnumed.124.269154 · 被引用次数：9 · 研究领域：Cardiac Imaging and Diagnostics、Medical Imaging Techniques and Applications、Radiopharmaceutical Chemistry and Applications

Recently, the U.S. Food and Drug Administration (FDA) approved 18F-labeled flurpiridaz as another PET myocardial perfusion imaging (MPI) radiotracer for clinical use in adult patients with known or suspected coronary artery disease (CAD). This decision was based on recent results of a second phase 3